Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-PKD: Empagliflozin in ADPKD
NCT06391450Phase 4Active, not recruiting
- Sponsor
- Hannover Medical School
- Start
- Jun 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Hannover Medical School. Started Jun 2024; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT06391450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391450.